Actively Recruiting
TRIple Negative Breast Cancer Markers In Liquid Biopsies Using Artificial Intelligence
Led by Jewish General Hospital · Updated on 2025-11-28
130
Participants Needed
3
Research Sites
416 weeks
Total Duration
On this page
Sponsors
J
Jewish General Hospital
Lead Sponsor
E
Exactis Innovation
Collaborating Sponsor
AI-Summary
What this Trial Is About
Triple negative breast cancer (TNBC) is the most aggressive of breast cancers and it is usually treated with chemotherapy even before surgery. In many cases, the chemotherapy completely "melts" the tumor and these patients do well. When the tumor is not eliminated by the chemotherapy, the patient receive more chemotherapy after surgery to decrease the chances of it coming back. Yet many of these patients don't need that extra chemotherapy and will do well in any case. One of the most exciting recent developments in cancer is the use of "liquid biopsies". It turns out that the tumor's DNA, RNA and proteins can be detected in small vesicles found in the patient's blood. Thanks to advances in Artificial Intelligence, there is now informatics tools to integrate many types of molecular information. Our industrial partner, MIMs, will apply novel informatics tools to generate a test using all the molecular information obtained from blood vesicles and tissue that will be able to find out early if tumor has spread outside of the breast, and how much tumor is left after surgery. The goal is hope to develop a multi-dimensional test for TNBC patients that can be used to decide how much treatment they need and if treatment given after surgery is working.
CONDITIONS
Official Title
TRIple Negative Breast Cancer Markers In Liquid Biopsies Using Artificial Intelligence
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Triple negative (ER negative, PR negative and Her2 negative as defined by local standards). ER <10% is acceptable.
- Patients who have completed a minimum of 8 weeks of neoadjuvant chemotherapy.
- A cohort of TNBC patients who are awaiting surgery that have clinical or radiological evidence of residual tumor prior to surgery. This evaluation will be made at the discretion of the treating physician.
OR A second cohort of TNBC patients will be recruited after surgery, in which pathological evaluation has demonstrated the presence of residual tumor post-surgery.
- Patients who can come to the clinic for standard of care follow-up within 6 weeks post-surgery and in the next 6 months after surgery.
- Patients who are willing to provide serial blood samples.
- Participants must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the study.
You will not qualify if you...
- Clinical or radiological evidence of metastatic disease.
- Patient with a recurrence of breast cancer.
- Patients who have not had neoadjuvant chemotherapy or less than 8 weeks of neoadjuvant chemotherapy.
- Patient who received radiotherapy treatment prior to surgery.
- Patients who are not capable of signing or understanding the informed consent form.
- Known infection with HIV or hepatitis.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
St. Joseph's Health Care London
London, Ontario, Canada, N6A 4V2
Actively Recruiting
2
The Ottawa Hospital Cancer Center
Ottawa, Ontario, Canada, K1H 8L6
Actively Recruiting
3
Jewish General Hospital
Montreal, Quebec, Canada, H3T 1E1
Actively Recruiting
Research Team
A
Adriana Aguilar, PhD
CONTACT
J
Josiane Lafleur, MSc
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here